Quality Assurance of HCV [hepatitis C virus]-Therapy With PegIntron Plus Rebetol in Drug-Substituted Patients - SUPPORT Project Post-Marketing Surveillance Study.

Trial Profile

Quality Assurance of HCV [hepatitis C virus]-Therapy With PegIntron Plus Rebetol in Drug-Substituted Patients - SUPPORT Project Post-Marketing Surveillance Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jul 2014

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Acronyms SUPPORT
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 31 Jul 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 31 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Dec 2008 Planned end date changed from Jan 2009 to Sep 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top